Specific tumor targeting and activation of Vγ9Vδ2 T cells by bi-specific nanobodies

Anita G.m Stam ,Rob C Roovers ,Renée De Bruin,Tanja D De Gruijl ,Paul Van Bergen En Henegouwen,Henk M.w Verheul ,Hans Van Vliet

doi:10.1186/2051-1426-2-s3-p127

Abstract

Meeting abstracts Gamma delta T cells expressing the Vγ9Vδ2 T cell receptor (TCR) are the most predominant γδ-T cell subset in peripheral blood accounting for approximately 1-5 % of all T cells. Vγ9Vδ2 T cells recognize phosphoantigens (pAg) such as isopentenyl pyrophosphate (IPP), a

Highlights

Gamma delta T cells expressing the Vg9Vδ2 T cell receptor (TCR) are the most predominant gδ-T cell subset in peripheral blood accounting for approximately 1-5 % of all T cells
Vg9Vδ2 T cells recognize phosphoantigens such as isopentenyl pyrophosphate (IPP), a naturally occurring pAg that can accumulate in tumor cells, resulting in activation, cytokine release and anti-tumor activity of Vg9Vδ2 T
Antitumor responses were observed in some patients, but overall results lack consistency. This might be related to systemic activation of Vg9Vδ2 T cells in these trials, not providing a specific trigger for these cells to accumulate at the tumor site

Summary

Introduction

Gamma delta T cells expressing the Vg9Vδ2 T cell receptor (TCR) are the most predominant gδ-T cell subset in peripheral blood accounting for approximately 1-5 % of all T cells. Specific tumor targeting and activation of Vg9Vδ2 T cells by bi-specific nanobodies From Society for Immunotherapy of Cancer 29th Annual Meeting National Harbor, MD, USA.

Results

Conclusion